Nucleic acid based gene therapy (NABT) is an emerging tool in human health, which uses viruses to deliver therapeutic DNA into cells. NABT is an exciting new approach for treating a wide range of diseases where gene therapy regimens lack sufficient specificity for their intended target cells. Nucleic acid-based gene therapy is a treatment that uses nucleic acid molecules that are delivered directly into the cells of the body to correct genetic defects. This can be done through injection, ingestion or prior to surgery or childbirth. Once inside the body’s cells, nucleic acids may cause corrective changes in a variety of different ways: by activating genes that code for desired characteristics; by degrading defective genes (e.g., if an abnormal gene is produced by your own body); by making an existing gene more flexible and able to produce new proteins efficiently; or by inserting them into other genetic sequences within cells, which may then induce a useful response.
Market Size Analysis:
According to a report by Altus Market Research titled, “Nucleic Acid Based Gene Therapy Global Market 2022 Opportunities And Strategies To 2030: By Nucleic Acid Technology: (Anti-Sense And Anti-Gene Oligonucleotides; Sirna And Rna Interference; Gene Transfer Therapy; Ribozymes; Aptamers); Application; End User“, the global nucleic acid-based gene therapy market size grew from $1,391.9 million in 2015 to $4,726.8 million in 2020 at a compound annual growth rate (CAGR) of 27.7%. The market is expected to grow from $4,726.8 million in 2020 to $7,282.9 million in 2025 at a rate of 9.0%. The market is then expected to grow at a CAGR of 15.4% from 2025 and reach $14,909.6 million in 2030.
Request Research Sample with Latest Industry Insights (221+ Pages Report): https://altusmarketresearch.com/reports/sample/43137
Market Growth Drivers:
Growth in the historic period in the nucleic acid-based gene therapy market resulted from technological advances in synthetic biology, advances in combinatorial chemistry and bioinformatics, increased healthcare expenditure, rising pharmaceutical R&D expenditure, and rise in public-private partnerships. The market was restrained by off-target specificity, challenges in nucleotide delivery to cells, instability of the nucleotides, inadequate reimbursements, challenges due to regulatory changes, low healthcare access, and limited number of treatment centers.
Going forward rise in healthcare expenditure, increasing prevalence of cancer and chronic diseases, rising geriatric population, rising geriatric population, increasing research and development spending and rising focus on gene therapy will drive the growth in the nucleic acid-based gene therapy market. Factors that could hinder the growth of the market in the future include high costs of therapy, stringent regulations, reimbursement challenges, and coronavirus pandemic.
Market Growth by Segments:
The nucleic acid-based gene therapy market is segmented by technology into anti-sense and anti-gene oligonucleotides, SiRNA and RNA Interference, gene transfer therapy, ribozymes, aptamers, and others.
The anti-sense and anti-gene oligonucleotides market was the largest segment of the nucleic acid-based gene therapy market segmented by technology, accounting for 92.90% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the nucleic acid-based gene therapy market segmented by technology, at a CAGR of 59.9% during 2020-2025.
Market Growth by Applications:
The nucleic acid-based gene therapy market is also segmented by application into oncology, muscular dystrophy/muscular disorders, rare diseases and others. The muscular dystrophy/muscular disorders market was the largest segment of the nucleic acid-based gene therapy market segmented by application, accounting for 61.4% of the total in 2020. Going forward, the oncology segment is expected to be the fastest growing segment in the nucleic-acid based gene therapy market segmented by application, at a CAGR of 18.1% during 2020-2025.
Market Growth by End Users:
The nucleic acid-based gene therapy market is also segmented by end-user into hospitals and clinics, academic and research institutes. The hospitals and clinics market was the largest segment of the nucleic acid-based gene therapy market segmented by end-user, accounting for 85.0% of the total in 2020. Going forward, the academic and research institutes segment is expected to be the fastest growing segment in the nucleic-acid based gene therapy market segmented by end-user, at a CAGR of 9.8% during 2020-2025.
Market Growth by Region:
North America was the largest region in the global nucleic acid-based gene therapy market, accounting for 46.2% of the total in 2020. It was followed by the Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the nucleic acid-based gene therapy market will be the Middle East and Eastern Europe where growth will be at CAGRs of 33.7% and 26.0% respectively. These will be followed by South America and Asia Pacific, where the markets are expected to register CAGRs of 21.0% and 20.4% respectively.
Market Growth by Key Players:
The global nucleic acid-based gene therapy market is fairly fragmented, with a large number of small players. The top ten competitors in the market made up to 16.40% of the total market in 2020. Major players in the market include Copernicus Therapeutics, Moderna Inc., Wave Life Sciences, Protagonist Therapeutics and Transgene.
uniQure NV, Sarepta Therapeutics Inc., Oxford Biomedica, Benitec Biopharma, PYC Therapeutics Limited, Imugene Ltd, Benitec Biopharma Ltd, EdiGene, Inc., GenScript, Biomics Biotechnologies (Nantong) Co., Ltd., Auris Medical Holding Ltd, Akcea Therapeutics, Arctoris Limited, BioNTech SE, Freeline Therapeutics, Celyad Oncology, Cellectis, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer AG, Voyager Therapeutics Inc., Roche Holding AG, Gilead Sciences, Inc., Amgen Brasil, Biogen Brazil, Novartis, Middle East Gene Therapy Company, DEVA, Biotchpharma, Gene Vector Technologies, BrainStorm Cell Therapeutics, Pluristem, Merck, Sanofi, Adcock Ingram
Strategies by Key Players:
Player-adopted strategies in the nucleic acid-based gene therapy market include strengthening product and service portfolio by strategic collaboration and partnerships for the product commercialization, bringing more advancements in new technologies to strengthening the overall business by strategic collaborations with companies having same business, expanding product portfolio by strategic collaborations and partnership with companies having advanced technologies, and strengthening business by focusing on bringing new technology advancements.
Market Growth by Investment Opportunities:
The top opportunities in the nucleic acid-based gene therapy market segmented by technology will arise in the anti-sense and anti-gene oligonucleotides segment, which will gain $1,290.7 million of global annual sales by 2025. The top opportunities in the nucleic-acid based gene therapy market segmented by application will arise in the muscular dystrophy/muscular disorders segment, which will gain $1,000.2 million of global annual sales by 2025. The top opportunities in the nucleic-acid based gene therapy market segmented by application will arise in the hospitals and clinics segment, which will gain $2,133.7 million of global annual sales by 2025. The nucleic acid-based gene therapy market size will gain the most in the USA at $915.0 million.
Market: Trend-based Strategies
Market-trend-based strategies for the nucleic-acid based gene therapy market include concentrating on undertaking various research initiatives and attain funding, carrying out strategic collaborations to integrate advanced technologies, partnering or acquiring competitor companies, increasing the number of pipeline studies to develop gene therapies and related drugs, investing in manufacturing facilities expansion and developing gene/genome editing tools.
Growth Strategies by Altus Market Research for Companies in the Market:
To take advantage of the opportunities, The AMR recommends the nucleic acid-based gene therapy companies to focus on partnerships and acquisitions, focus on gene editing, expanding in emerging markets, scale up through collaborations, offer competitive pricing, participate in gene therapy seminars and conferences and to focus on collaborating with hospitals.